Evaluation Of Veliparib (V) And Temozolomide (Tmz) In A Phase 2 Randomized Study Of The Efficacy And Tolerability Of V Plus Tmz Or Carboplatin (C) And Paclitaxel (P) Vs Placebo (Plc) Plus C/P In Patients (Pts) With Brca1 Or Brca2 Mutations And Metastatic Breast Cancer